Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586094 | 0.90 | NCF1 (0.42) | NCF1PLAUKDM4ENOS2BACE1 | |
| SCHEMBL30546638 | 0.90 | NCF1 (0.42) | NCF1PLAUKDM4ENOS2BACE1 | |
| SCHEMBL1765925 | 0.76 | BACE1 (0.48) | NCF1PLAUKDM4ENOS2BACE1 | |
| Sulfuric Acid SCHEMBL9849843 | 0.74 | NOS3 (0.41) | NCF1PLAUKDM4ENOS2BACE1 | |
| SCHEMBL22337665 | 0.69 | CRHBP (0.30) | — | |
| Sulfuric Acid SCHEMBL2243571 | 0.68 | NOS2 (0.48) | NCF1PLAUKDM4ENOS2BACE1 | |
| SCHEMBL6412343 | 0.66 | PIK3CD (0.40) | NCF1PLAUKDM4ENOS2BACE1 | |
| SCHEMBL2901701 | 0.64 | NOS2 (0.50) | NCF1KDM4ENOS2BACE1GABRP | |
| SCHEMBL10758069 | 0.64 | BACE1 (0.43) | NCF1PLAUKDM4ENOS2BACE1 | |
| SCHEMBL29414112 | 0.64 | NOS2 (0.50) | NCF1KDM4ENOS2BACE1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304158-B2 | Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) | INDEVUS PHARMACEUTICALS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| US-20060194830-A1 | Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) | INDEVUS PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-7057047-B2 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone | INDEVUS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | claimed |
| EP-1490363-B1 | METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE | INDEVUS PHARMACEUTICALS INC (US) | 2006-01-25 | — | — | EP | claimed |
| US-20050288322-A1 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone | INDEVUS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | claimed |
| EP-1490363-A1 | METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE | Warner-Lambert Company LLC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030191315-A1 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone | ENDO PHARMACEUTICALS INC. | 2003-10-09 | — | — | US | claimed |
| WO-2003082870-A1 | METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | claimed |
| US-7304158-B2 | Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) | INDEVUS PHARMACEUTICALS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060194830-A1 | Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) | INDEVUS PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-7057047-B2 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone | INDEVUS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1490363-B1 | METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE | INDEVUS PHARMACEUTICALS INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050288322-A1 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone | INDEVUS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-6949653-B2 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone | INDEVUS PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1490363-A1 | METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE | Warner-Lambert Company LLC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030191315-A1 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone | ENDO PHARMACEUTICALS INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003082870-A1 | METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288322-A1 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone | NT5C3B, NT5C, CYP2J2 | NCF1 1620/4885PLAU 1910/4885KDM4E 3157/4885 |
| US-20030191315-A1 | Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone | NT5C, NT5C3B, UGT8 | NCF1 1288/4885PLAU 2222/4885KDM4E 3343/4885 |
| US-20060194830-A1 | Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) | NT5C, NT5C3B, UGT8 | NCF1 1072/4885PLAU 2570/4885KDM4E 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.